Compare BKKT & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKKT | KRMD |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.5M | 195.7M |
| IPO Year | N/A | 2019 |
| Metric | BKKT | KRMD |
|---|---|---|
| Price | $9.24 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $21.50 | $6.50 |
| AVG Volume (30 Days) | ★ 1.2M | 137.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,127,366.00 |
| Revenue This Year | N/A | $20.32 |
| Revenue Next Year | $261.39 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $6.87 | $2.08 |
| 52 Week High | $49.79 | $6.61 |
| Indicator | BKKT | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 44.13 |
| Support Level | $8.86 | $4.08 |
| Resistance Level | $10.51 | $4.34 |
| Average True Range (ATR) | 0.60 | 0.20 |
| MACD | 0.30 | 0.02 |
| Stochastic Oscillator | 91.51 | 55.32 |
Bakkt Inc builds digital financial infrastructure designed to support institutional participation in the digital asset economy. The company platform is built to accommodate various digital assets and offers its clients the flexibility to build a product that aligns with its vision and customers' needs. Its services include Bakkt Markets, Bakkt Agent, Bakkt Global.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.